Noxopharm Advances SOF-SKN™ to First Human Trials in Australia

An announcement from Noxopharm Ltd. ( (AU:NOX) ) is now available.

Noxopharm Limited has submitted an application to the Human Research Ethics Committee for approval to conduct the HERACLES clinical trial, following successful preclinical testing. This trial marks the first-in-human study for SOF-SKN™, a novel drug candidate aimed at treating autoimmune diseases, specifically targeting cutaneous lupus erythematosus as a proof of concept. Conducting the trial in Australia allows Noxopharm to benefit from local expertise and federal R&D tax incentives, potentially positioning the company as a leader in autoimmune disease treatment. The success of this trial could pave the way for further development of the Sofra technology for other immune-related conditions.

More about Noxopharm Ltd.

Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance a wide range of mRNA medicines and build a pipeline of new drugs targeting inflammation, autoimmunity, and oncology.

YTD Price Performance: -11.11%

Average Trading Volume: 87,099

Technical Sentiment Signal: Buy

Current Market Cap: A$23.38M

For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.